Oral Immunoproteasome Inhibitor Program AutoImmune / Inflammatory Diseases

Preclinical

  • Developing LMP7 and dual LMP7/LMP2 selective inhibitors to target various autoimmune disorders such as inflammatory bowel diseases (IBD), lupus and psoriasis

  • Selective immunoproteasome inhibition blocks IL-23 production and T cell signaling which drives highly pathogenic T-cell populations involved in the initiation of many autoimmune diseases

  • Designed to be devoid of cytotoxicity inherent with pan proteasome drugs

  • Multiple orally bioavailable series of highly selective reversible covalent inhibitors have been created